论文部分内容阅读
内皮素Ａ受体阻滞剂可抑制内皮素引起血管暂时舒张后的持续性收缩，使血管舒张，可治疗与内皮素有关的血管收缩性疾病。ＳＢ２０９６７０除抑制ＥＴＡＲ，ＥＴＢ１Ｒ外，还能抑制介导收缩反应的ＥＴＢ２Ｒ，能更全面地阻滞收缩反应；ＢＱ－１５３和ＢＱ－１２３等扩张血管时不影响血压；ＦＲ１３９３１抑制平滑肌细胞增殖，可能对ＥＴ－１引起的肺动脉高压有效；具有口服活性的Ｌ－７４４４５３，Ｌ－７５４１４２，Ａ－１２７７２２，ＰＤ０１２５２７，ＰＤ１５５０８０，ＳＢ２１７２４２，ＳＢ２０９６７０，ＢＭＳ－１８２７４等治疗更方便；ＰＤ１５１２４２可形成放射性结合物，使其应用更广。
Endothelin A receptor blocker can inhibit endothelins caused by sustained vasoconstriction of the blood vessels after a temporary contraction, so that vasodilatation can be treated with endothelin-related vasoconstrictive disease. In addition to ETAR and ETB1R inhibition, SB209670 can inhibit ETB2R that mediates contractile response, which can more completely block the contractile response; BQ-153 and BQ-123 do not affect blood pressure when dilated blood vessels; FR13931 inhibits smooth muscle cell proliferation, ET-1-induced pulmonary hypertension; oral administration of L-744453, L-754142, A-127722, PD012527, PD155080, SB217242, SB209670, BMS-18274 and other treatment more convenient; PD151242 can form radioactive conjugates, More widely used.